ePT--the Electronic Newsletter of Pharmaceutical Technology
Millennium Pharmaceuticals, Inc. entered into an agreement to acquire biopharmaceutical company AnorMED, Inc. (Langley, BC, Canada) for $515 million.
Cambridge, MA (Sept. 26)-Millennium Pharmaceuticals, Inc. (www.mlnm.com) entered into an agreement to acquire biopharmaceutical company AnorMED, Inc. (Langley, BC, Canada, www.anormed.com) for $515 million. Millennium will acquire all AnorMED’s outstanding common shares for US$12.00 per share in cash. The total purchase is 40% more than Genzyme Corporation’s (Cambridge, MA, www.genzyme.com) unsolicited tender offer ($8.55 cash per share) on Sept. 1, 2006.
The deal will give Millennuim access to AnorMED’s “Mozobil” lead hematology-oncology product, which is in late-stage Phase III trials in cancer patients undergoing stem cell transplants. The company expects the product to be on the market in 2008.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.